Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a manufacturer-issued press release. If approved, the release said this ...
In bronchiectasis, the walls of the airways ... which require treatment with antibiotics and sometimes result in patients being hospitalised. Brensocatib given at two daily oral doses (10 mg ...
Zacks Investment Research on MSN7d
Insmed's NDA for Lung Disease Drug Gets FDA's Priority ReviewInsmed Incorporated INSM announced that the FDA has accepted its new drug application (“NDA”) seeking approval of its ...
Lung resection is to be limited as far as possible, since bronchiectasis will develop ... may benefit from the addition of antibiotic prophylaxis. Acute infections should be treated promptly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback